101 related articles for article (PubMed ID: 2255843)
1. Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride.
Jamaludin A; Mohamad M; Navaratnam V; Yeoh PY; Wernsdorfer WH
Trop Med Parasitol; 1990 Sep; 41(3):268-72. PubMed ID: 2255843
[TBL] [Abstract][Full Text] [Related]
2. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.
Edstein MD; Veenendaal JR; Scott HV; Rieckmann KH
Chemotherapy; 1988; 34(5):385-92. PubMed ID: 3180907
[TBL] [Abstract][Full Text] [Related]
3. Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone.
Edstein MD; Veenendaal JR; Rieckmann KH
Chemotherapy; 1990; 36(3):169-76. PubMed ID: 2186899
[TBL] [Abstract][Full Text] [Related]
4. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults.
Watkins WM; Mberu EK; Nevill CG; Ward SA; Breckenridge AM; Koech DK
Trans R Soc Trop Med Hyg; 1990; 84(4):492-5. PubMed ID: 2091335
[TBL] [Abstract][Full Text] [Related]
5. Human pharmacokinetics of proguanil and its metabolites.
Bygbjerg I; Ravn P; Rønn A; Flachs H; Hvidberg EF
Trop Med Parasitol; 1987 Jun; 38(2):77-80. PubMed ID: 3629140
[TBL] [Abstract][Full Text] [Related]
6. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.
Wangboonskul J; White NJ; Nosten F; ter Kuile F; Moody RR; Taylor RB
Eur J Clin Pharmacol; 1993; 44(3):247-51. PubMed ID: 8491239
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Thapar MM; Ashton M; Lindegårdh N; Bergqvist Y; Nivelius S; Johansson I; Björkman A
Eur J Clin Pharmacol; 2002 Apr; 58(1):19-27. PubMed ID: 11956669
[TBL] [Abstract][Full Text] [Related]
8. Human pharmacokinetics of chloroquine and proguanil delivered in a single capsule for malaria chemoprophylaxis.
Touze JE; Keundjian A; Fusai T; Doury JC
Trop Med Parasitol; 1995 Sep; 46(3):158-60. PubMed ID: 8533017
[TBL] [Abstract][Full Text] [Related]
9. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz.
Soyinka JO; Onyeji CO
Eur J Pharm Sci; 2010 Feb; 39(4):213-8. PubMed ID: 19961932
[TBL] [Abstract][Full Text] [Related]
10. The multiple dose pharmacokinetics of proguanil.
Helsby NA; Edwards G; Breckenridge AM; Ward SA
Br J Clin Pharmacol; 1993 Jun; 35(6):653-6. PubMed ID: 8329294
[TBL] [Abstract][Full Text] [Related]
11. A statistical analysis of the antimalarial activity of proguanil and cycloguanil in human volunteers.
Yeo AE; Edstein MD; Shanks GD; Rieckmann KH
Ann Trop Med Parasitol; 1994 Dec; 88(6):587-94. PubMed ID: 7893172
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo antimalarial activity of proguanil combined with dapsone against cycloguanil-resistant Plasmodium falciparum isolates.
Edstein MD; Yeo AE; Shanks GD; Rieckmann KH
Acta Trop; 1997 Sep; 66(3):127-35. PubMed ID: 9210963
[TBL] [Abstract][Full Text] [Related]
13. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ
Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893
[TBL] [Abstract][Full Text] [Related]
14. OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil.
Matthaei J; Seitz T; Jensen O; Tann A; Prukop T; Tadjerpisheh S; Brockmöller J; Tzvetkov MV
Clin Pharmacol Ther; 2019 Jan; 105(1):190-200. PubMed ID: 29882324
[TBL] [Abstract][Full Text] [Related]
15. Lack of a pharmacokinetic interaction between atovaquone and proguanil.
Gillotin C; Mamet JP; Veronese L
Eur J Clin Pharmacol; 1999 Jun; 55(4):311-5. PubMed ID: 10424325
[TBL] [Abstract][Full Text] [Related]
16. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.
Wattanagoon Y; Taylor RB; Moody RR; Ochekpe NA; Looareesuwan S; White NJ
Br J Clin Pharmacol; 1987 Dec; 24(6):775-80. PubMed ID: 3440097
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.
Helsby NA; Ward SA; Edwards G; Howells RE; Breckenridge AM
Br J Clin Pharmacol; 1990 Oct; 30(4):593-8. PubMed ID: 2291871
[TBL] [Abstract][Full Text] [Related]
18. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
[TBL] [Abstract][Full Text] [Related]
19. Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound.
Helsby NA; Ward SA; Parslew RA; Friedmann PS; Rhodes LE
Acta Derm Venereol; 1998 Mar; 78(2):81-3. PubMed ID: 9534880
[TBL] [Abstract][Full Text] [Related]
20. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.
Ward SA; Watkins WM; Mberu E; Saunders JE; Koech DK; Gilles HM; Howells RE; Breckenridge AM
Br J Clin Pharmacol; 1989 Jun; 27(6):781-7. PubMed ID: 2757894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
